« Return to News | Drug Sponsors

Arrowhead enters into antibody candidate evaluation agreement with Merck

Wednesday, August 15, 2012 11:27 AM

Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has entered into an agreement with global healthcare company Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

Arrowhead acquired the program through its purchase of Alvos Therapeutics in April 2012. Merck will bear the costs involved in evaluating the candidate.

“We are excited to be working with Merck as they evaluate this antibody candidate,” said Dr. Chris Anzalone, president and CEO of Arrowhead. “We believe that our human-derived library of targeting peptides and novel receptors is the world’s largest and can be used with many classes of drugs across multiple indications to enhance efficacy and decrease side effects.”

Arrowhead’s target discovery and delivery platform consists of a large library of unique human-derived peptide sequences selected for their ability to bind cell surface targets and rapidly internalize within cells of more than 30 distinct tissues and multiple tumor types. The discovery process, which involves screening directly in human patients under strict ethical guidelines, has identified novel receptor targets as well as novel binding sites for validated targets. Additional antibody and peptide-based targeting programs for oncology and other therapeutic areas are currently being identified and assessed for internal development or partnering.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.